The two-year study, conducted at 23 U.S. sites, evaluated the safety and efficacy of M6-C compared to ACDF for the treatment of single-level symptomatic cervical radiculopathy with or without spinal cord compression.
“Patients with degenerative cervical radiculopathy treated with the M6-C disc had significant improvements in neck and arm pain, function and quality of life scores,” Frank Phillips, MD, co-author of the study, said in a Jan. 28 news release.
Furthermore, M6-C patients had a notable reduction of pain and opioid use compared to ACDF patients, Dr. Phillips said. “At 24 months, patients in the ACDF group who were still using pain medications had a seven times higher rate of opioid use than those in the M6-C disc group.”
The two-year study compared 160 M6-C subjects to a matched subset of 189 ACDF controls. The overall success rate for the primary endpoint for the M6-C disc patients was 86.8 percent at 24 months and 79.3 percent in the control group.
Click here for more details on the study.
More articles on spine:
Why Florida is becoming a major battleground for orthopedics
Spine surgeon, inventor files patent infringement suit against NuVasive
14 key thoughts on bundled payments in spine surgery
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
